Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 20/20 | 0.64 |
| ▸ | ESR1 | P03372 | 15/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226889 | 0.83 | CEPT1 (0.53) | ESR2ESR1HDAC6 | |
| SCHEMBL28616475 | 0.79 | ESR2 (0.56) | ESR2ESR1HDAC6 | |
| SCHEMBL2399039 | 0.78 | ESR2 (1.00) | ESR2ESR1HDAC6 | |
| SCHEMBL4463948 | 0.77 | ESR2 (0.47) | ESR2ESR1HDAC6 | |
| SCHEMBL27700170 | 0.76 | ESR2 (0.80) | ESR2ESR1HDAC6 | |
| SCHEMBL5426383 | 0.76 | ESR2 (0.68) | ESR2ESR1HDAC6 | |
| SCHEMBL3930187 | 0.76 | ESR2 (1.00) | ESR2ESR1HDAC6 | |
| SCHEMBL5424079 | 0.76 | ESR2 (0.68) | ESR2ESR1HDAC6 | |
| SCHEMBL1376248 | 0.75 | ESR2 (1.00) | ESR2ESR1HDAC6 | |
| SCHEMBL1379350 | 0.75 | ESR2 (1.00) | ESR2ESR1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212923-A1 | Phosphate Derivatives of Substituted Benzoxazoles | PFIZER INC. | 2011-09-01 | — | — | US | claimed |
| EP-2250180-A1 | PHOSPHATE DERIVATIVES OF SUBSTITUTED BENZOXAZOLES | Wyeth LLC (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009100335-A1 | PHOSPHATE DERIVATIVES OF SUBSTITUTED BENZOXAZOLES | WYETH (US) | 2009-08-13 | — | — | WO | claimed |
| CN-101423500-A | Substituted benzoxazoles and analogues as estrogenic agents | WYETH CORP (US) | 2009-05-06 | — | — | CN | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| CN-100443477-C | Substituted benzo * oxazoles and analogs as estrogenic agents | WYETH CORP (US) | 2008-12-17 | — | — | CN | claimed |
| CN-101044126-A | Prodrug substituted benzoxazoles as estrogenic agents | WYETH CORP (US) | 2007-09-26 | — | — | CN | claimed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | claimed |
| EP-1781628-A2 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | Wyeth a Corporation of the State of Delaware (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006026316-A2 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-03-02 | — | — | US | claimed |
| CN-1646504-A | Substituted benzoxazoles and analogs as estrogenic agents | WYETH CORP (US) | 2005-07-27 | — | — | CN | claimed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | claimed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | claimed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | claimed |
| EP-3782616-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885HDAC6 1770/4885 |
| US-20110212923-A1 | Phosphate Derivatives of Substituted Benzoxazoles | ESR2, GPER1, ESR1 | ESR2 1/4885ESR1 3/4885HDAC6 4186/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR2 5/4885ESR1 4/4885HDAC6 1524/4885 |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885HDAC6 1892/4885 |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | ESR1, CYP19A1, ESR2 | ESR2 3/4885ESR1 1/4885HDAC6 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.